IL-17is demonstrate efficacy in SpA tx Comparable with TNFis & JAKis in terms of achieving ASAS40 response rates IL-17is are generally well-tolerated w/⬇️TB risk (very important tx consideration esp in Asia) But watch out for candidal infx, IBD exacerbation @RheumNow #APLAR25 https://t.co/rSUJlZOhKV